CollabNet Acquires SourceForge

CollabNet acquires SourceForge from VA Software and VA Software gains an equity stake in CollabNet.

CollabNet and VA Software have announced a deal in which CollabNet has acquired the SourceForge Enterprise Edition business from VA Software in exchange for VA Software gaining an equity ownership stake in CollabNet.

The companies announced the deal at the close of the market on April 24. The parties have also entered into a 30-month media relationship for online advertising services.SourceForge Enterprise Edition is a strategic addition to CollabNet, bringing the two collaborative software development solutions for distributed teams under the same roof.

The combined entity will support more than 300 enterprise customers with more than 1.1 million users in dozens of countries, the company said. CollabNet is based in Brisbane, Calif., and VA Software is based in Fremont, Calif.

This combined entity signals the arrival of a new era in software development, in which distributed teams working on modern Web-based collaborative platforms have now become the norm for companies seeking to gain competitive advantage on a global basis, CollabNet officials said.

SourceForge Enterprise Edition, along with CollabNet's entire product portfolio - CollabNet Enterprise Edition, CollabNet CUBiT and Subversion - will be fully supported and enhanced over time, CollabNet officials said.

"The market for globally distributed software development solutions is growing rapidly as the need for interconnected applications and software development teams has now become the norm," Bill Portelli, CEO of CollabNet, said in a statement.

Copyright 2007 by Ziff Davis Media, Distributed by United Press International

Citation: CollabNet Acquires SourceForge (2007, April 25) retrieved 26 April 2024 from https://phys.org/news/2007-04-collabnet-sourceforge.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Researchers develop irreversible inhibitor to address proteins that have acquired drug-resistant mutations

0 shares

Feedback to editors